SEOM clinical guidelines for the management of metastatic breast cancer 2013. (Q46011982)

18 December 2017

title

SEOM clinical guidelines for the management of metastatic breast cancer 2013. (English)

1 reference

18 December 2017

main subject

metastatic breast cancer

1 reference

A Llombart Cussac

1

1 reference

18 December 2017

J de la Haba Rodríguez

2

1 reference

18 December 2017

A Ruiz Simón

3

1 reference

18 December 2017

I Álvarez López

4

1 reference

18 December 2017

J Cortés Castán

5

1 reference

18 December 2017

SEOM

6

1 reference

18 December 2017

publication date

23 October 2013

1 reference

18 December 2017

Clinical and Translational Oncology

published in

1 reference

18 December 2017

volume

15

1 reference

18 December 2017

issue

12

1 reference

18 December 2017

page(s)

1004-1010

1 reference

18 December 2017

SEOM clinical guidelines for the treatment of metastatic breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

1st International consensus guidelines for advanced breast cancer (ABC 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

The sequential use of endocrine treatment for advanced breast cancer: where are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Combination anastrozole and fulvestrant in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

The role of chemotherapy and targeted agents in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

SEOM guidelines for the treatment of bone metastases from solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12094-013-1095-0

Progress against solid tumors in danger: the metastatic breast cancer example

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24151043

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24151043

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24151043

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12094-013-1095-0

1 reference

18 December 2017

1 reference

18 December 2017